MEDI 565

Drug Profile

MEDI 565

Alternative Names: AMG-211; CEA BiTE mAb; MEDI-565; MT-111

Latest Information Update: 25 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Micromet Inc
  • Developer Amgen; MedImmune; University Medical Center Groningen
  • Class Antineoplastics; Bispecific antibodies
  • Mechanism of Action T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Gastrointestinal cancer; Solid tumours

Most Recent Events

  • 09 Jan 2018 Amgen completes a phase I trial in Gastrointestinal cancer (Late-stage disease, Second-line therapy or greater) in Germany and Netherlands (IV) (NCT02291614)
  • 01 Jan 2018 Discontinued - Phase-I for Gastrointestinal cancer (Late-stage disease) in USA (IV) (AstraZeneca pipeline, May 2018)
  • 01 Jan 2018 Discontinued - Phase-I for Gastrointestinal cancer (Late-stage disease, Second-line therapy or greater) in Germany (IV) (AstraZeneca pipeline, May 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top